Wuxi Biologics (shanghai) Co., Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceuticals (suzhou) Co., Ltd.

Wuxi Biologies (shanghai) Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Gennady Gololobov

Jing Li

Jianqing Xu

Zhuozhi Wang

Yong Sen Zheng

Dong Sheng Li

Dong Li

Xinhua Zhang

Baotian Yang

Zhewei Tang

Yong Zheng

The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.

Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.

Monoclonal antibodies to programmed death 1 (PD-1)

Growing community of inventors

Gaithersburg, MD, United States of America

Gennady Gololobov